Brain Metastases, Breast Cancer
Conditions
Keywords
Breast cancer, Brain metastases, Pyrotinib, Vinorelbine, HER2
Brief summary
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER1, HER2 and HER4 receptors. This study is a single-arm, prospective, open label clinical study of pyrotinib plus vinorelbine as the therapy of brain metastases from HER2-positive metastatic breast cancer.
Interventions
Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age18-75 years. 2. ECOG performance status ≤2. 3. Histologically confirmed HER2 positive advanced breast cancer. 4. Prior to anthracyclines and taxanes (neoadjuvant, adjuvant and metastatic setting). Received ≤4 regimes in metastatic setting. Prior to trastuzumab is allowed. 5. Not received whole brain radiotherapy (WBRT) or recurrence after WBRT. 6. Controlled CNS symptoms (headache, dizziness, lethargy, nausea etc.). 7. Patients with CNS metastasis; at least one CNS metastases with a longest diameter ≥1 cm and a diameter perpendicular to the longest diameter should be ≥0.5 cm; 8. Signed the informed consent form prior to patient entry.
Exclusion criteria
1. Participated in other drug clinical trials within 4 weeks before the start of the study; 2. Received radiotherapy, chemotherapy, surgery and target therapy within 4 weeks before the start of the study; 3. Received endocrine therapy within 7 days before the start of the study; 4. Suitable for surgical resection; 5. Accompanied by rapid progress of organ invasion; 6. Factors influencing the usage of oral administration (such as unable to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction etc.). 7. Prior to pyrotinib or vinorelbine or anti-HER2 TKI drugs; 8. Allergies to any compounds of experimental drugs; 9. CNS disorders or mental disorders, history of clear neurological or mental disorders, including epilepsy or dementia; 10. Other malignancies within 5 years, except cured in-situ of uterine cervix carcinoma , skin basal cell carcinoma and squamous-cell carcinoma. 11. Any other situations judged by investigator as not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) of CNS | Estimated up to 1 year | ORR, defined as proportion of complete response and partial response according to RANO-Brain Metastases (RANO-BM) criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to progression (TTP) | Estimated up to 1 year | TTP, defined as the time from the date of informed consent until the date of disease progression (PD), either CNS PD or extracranial PD, whichever comes first. |
| OS (overall survival) | Estimated up to 1 year | OS, defined as the time from the date of informed consent until to the date of death, regardless of the cause of death. |
| Time to radiotherapy | Estimated up to 1 year | Time to radiotherapy, defined as the time from the date of informed consent until to the date of radiotherapy. |
Countries
China
Contacts
Primary ContactPeng Yuan, M.D.
Outcome results
None listed